Drug Profile
MV NB 02
Alternative Names: GD2-GD3 Vaccine; MV Neuro; MV-NB-02; Neuroblastoma vaccine - MabVax/MSKCCLatest Information Update: 29 May 2022
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Memorial Sloan-Kettering Cancer Center; Y-mAbs Therapeutics
- Class Cancer vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Neuroblastoma
Most Recent Events
- 08 Apr 2022 Updated efficacy and adverse events data from a phase II trial in Neuroblastoma presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 31 Dec 2019 Memorial Sloan-Kettering Cancer Center has patent protection for MV NB02 vaccine in USA, before December 2019
- 12 Dec 2019 Y-mAbs Therapeutics plans a multicenter phase II trial for Neuroblastoma in 2020